Jazz Pharma Bagged Promising Blood Cancer Drug from Celator Takeover

1
Jazz Pharma Bagged Promising Blood Cancer Drug
from Celator Takeover
2

• The strategic alliance from the 1.5
  billion takeover of US based Celator
  Pharmaceuticals by Ireland based Jazz
  Pharmaceuticals will add promising VYXEOS into
  their portfolio.

3

• Dublin headquartered Jazz Pharmaceuticals will
  acquire the Celator Pharmaceuticals for 30.25
  per share in cash or around 1.5 billion. VYXEOS
  (CPX-351) is an investigational candidate of
  Celator for the treatment of a rare blood cancer,
  acute myeloid leukemia (AML).

4
(No Transcript)
5

• Celator have not earned revenue till now but its
  promising drug VYXEOS promises huge earnings for
  the acquirer. VYXEOS received Breakthrough
  Therapy designation from US FDA and Orphan Drug
  designation from US FDA and European Commission
  for the treatment of AML which will provide the
  company a long period of market exclusivity.

6
(No Transcript)
7

• Jazz Pharmaceuticals has the US FDA approved
  narcolepsy drug, Xyrem. During the fiscal year
  2015, Xyrem brought 955 million for the company
  spiking the companys annual revenue growth by
  around 23. From its oncology portfolio, Jazz
  sells Erwinaze for the treatment of rare blood
  cancer, acute lymphoblastic leukemia (ALL) and
  Defitelio to treat rare and fatal complication of
  stem cell transplants in cancer patients.

8

• Now the addition of VYXEOS will broaden Jazzs
  oncology portfolio. Jazz will get worldwide
  development and commercialization rights
  of VYXEOS.

9

• The market value of Jazz is about 9 billion and
  approximately 1 billion in cash as of March 31.
  The acquisition of Celator will likely fasten the
  earning per share initiating in 2018. Transaction
  is expected to close in the third quarter of
  2016.

10

• Apart from adding a new orphan product which will
  help in the generation of short and long term
  revenue, the acquisition will also support the
  expansion of its international commercial
  platform.

11

• To Know More Update, Visit Us

http//medgenera.com/